 |
|
Hormone use related to lower risk of macular degeneration in postmenopausal women
April 15, 2008Women who take postmenopausal hormones appear to have a lower risk of developing advanced stages of the eye disease age-related macular degeneration, especially if they had also taken oral contraceptives in the past, according to a report in the April issue of Archives of Ophthalmology, one of the JAMA/Archives journals.
Age-related macular degeneration (AMD) is the leading cause of vision loss and blindness among older adults, affecting 1.75 million Americans, according to background information in the article. "Although genetics plays a key role in susceptibility to AMD, environmental factors, such as smoking, are also important," the authors write. "Evidence of higher rates of AMD in women than in men and links between AMD and cardiovascular disease suggested a role for estrogen in the etiology" or development of the condition.
Diane Feskanich, Sc.D., of Brigham and Women's Hospital and Harvard Medical School, Boston, and colleagues assessed estrogen-related factors such as postmenopausal hormone use, past use of oral contraceptives, ages at first period and menopause and childbirth history in 74,996 post-menopausal women in the Nurses' Health Study. Between 1980 and 2002, 554 of the women developed early (beginning-stage) AMD and 334 women developed neovascular (more advanced, involving the formation of new blood vessels) AMD.
"Current postmenopausal hormone users had a notable 48 percent lower risk of neovascular AMD compared with those who had never used postmenopausal hormones, although risk did not decline linearly with longer durations of use," the authors write. "Risk was lowest for postmenopausal hormone users who had used oral contraceptives in the past."
In contrast, risk of early AMD was 34 percent higher among current postmenopausal hormone users and oral contraceptive use was not associated with early AMD risk. "The higher risk of early AMD among postmenopausal hormone users was unexpected and in apparent conflict with the observed inverse association for neovascular AMD," the authors write. Women who had given birth had a 26 percent lower risk of early AMD.
"Taken together, these findings suggest a role for estrogen in the pathogenesis of AMD that requires further research in specific early and late signs of disease," they conclude.
JAMA and Archives Journals
"Current postmenopausal hormone users had a notable 48 percent lower risk of neovascular AMD compared with those who had never used postmenopausal hormones, although risk did not decline linearly with longer durations of use," the authors write. "Risk was lowest for postmenopausal hormone users who had used oral contraceptives in the past."
In contrast, risk of early AMD was 34 percent higher among current postmenopausal hormone users and oral contraceptive use was not associated with early AMD risk. "The higher risk of early AMD among postmenopausal hormone users was unexpected and in apparent conflict with the observed inverse association for neovascular AMD," the authors write. Women who had given birth had a 26 percent lower risk of early AMD.
"Taken together, these findings suggest a role for estrogen in the pathogenesis of AMD that requires further research in specific early and late signs of disease," they conclude.
JAMA and Archives Journals
Postmenopausal Current Events and Postmenopausal News RSSMayo researchers find robotic repair for vaginal prolapse has significant benefits
New Mayo Clinic research has found that robotic surgery for vaginal prolapse dramatically reduces patient hospital stay and recovery time.
Scientists uncover new key to the puzzle of hormone therapy and breast cancer
The use of postmenopausal hormone therapy has decreased over time in the United States, which researchers suggest may play a key role in the declining rate of atypical ductal hyperplasia, a known risk factor for breast cancer.
Postmenopausal women with higher testosterone levels
Postmenopausal women who have higher testosterone levels may be at greater risk of heart disease, insulin resistance and the metabolic syndrome compared to women with lower testosterone levels.
Study shows hormone replacement therapy decreases mortality in younger postmenopausal woman
Hormone replacement therapy (HRT) to treat menopausal estrogen deficiency has been in widespread use for over 60 years. Several observational studies over the years showed that HRT use by younger postmenopausal women was associated with a significant reduction in total mortality; available evidence supported the routine use of HRT to increase longevity in postmenopausal women.
Novel, soy-based SE5-OH containing Natural S-equol supplement reduced hot flash frequency by nearly 59 percent
SE5-OH containing Natural S-equol, a novel soy germ-based ingredient in a supplement, improved menopausal symptoms, including significantly reducing hot flash frequency by nearly 59 percent, according to a peer-reviewed study in Japanese women.
Researchers believe hormone therapy should not be stopped prior to mammograms
Researchers from Boston University School of Medicine (BUSM) are recommending that menopausal women on hormone therapy (HT) continue their treatment prior to having their annual mammogram screenings.
Study of adjuvant endocrine treatment for breast cancer reveals cost of noncompliance
The largest study in the world of treatments for post menopausal, hormone positive breast cancer has shown that patients who continue to take exemestane or tamoxifen do significantly better than patients who start to take one or other drug (or tamoxifen followed exemestane) but then stop.
Postmenopausal women benefit from endurance training as much as younger women
Marilyn Graham was 56 when she signed up for a grueling hour of cycling each morning for 12 weeks, occasionally decked out in a mask, a heart monitor and a bag of intravenous fluid and subjected to needle pricks to obtain blood samples.
Seizure drug enhances sleep for women with hot flashes
Gabapentin, a drug initially used to treat seizures, improves sleep quality in menopausal women with hot flashes, University of Rochester Medical Center researchers report online and in the September issue of the Journal of Women's Health.
Buyer beware: Estrogen supplements not as effective as claimed
Dietary supplements claiming to help postmenopausal women with bone health may not be doing what they say, according to new research from Purdue University.
More Postmenopausal Current Events and Postmenopausal News Articles
|
Physicians' reference guide for the diagnosis and treatment of postmenopausal osteoporosis by John F Aloia (Author) | |
 |
Femgest Progesterone 2/2 fl oz Cream by Home Health An organically based form of progesterone cream designed for women of all ages, FemGest provides a gentle, holistic approach to your body's need for balance. Featuring progesterone combined with soothing aloe vera and grapefruit extract, FemGest is ideal for those times when you want a supportive, soothing cream that harmonizes with your unique nature. |
|
Peri- and Postmenopausal Mood and Associated Symptoms | |
 |
Healthy Aging Nutraceuticals Osteo Support 120 Tab by Healthy Aging Nutraceuticals Healthy bones need more than just calcium, and this is the best product we have found. A combination mineral, nutrient and herbal formulation, Osteo Support contains all the supplements you need to build and protect bones. We use it most often for bone injuries and for pre- and postmenopausal women who want a good quality calcium supplement. |
 |
Treatment of the Postmenopausal Woman: Basic and Clinical Aspects, 3rd Edition by Rogerio A. Lobo (Editor) For anyone who treats postmenopausal women, this latest edition of Rogerio Lobo's classic work combines the best from two well-known references: Menopause, and the second edition of Treatment of the Postmenopausal Woman. By adding significant discussions of the basic science behind menopause, it is possible to objectively assess the clinical value and limitations of current approaches to treatment and provide a basis and rationale for strategies that will result in better individualized and specialized care. Not only does the third edition discuss diagnosis and treatment of menopause but it covers biological, anatomical, physiological, pathobiological, and pharmacological aspects as well bringing together, in one source, all of the information needed to understand and treat postmenopausal... |
|
Hormone therapy debate continues post WHI: the effects of postmenopausal HT on both heart disease risk and breast cancer risk remain unclear.(Women's Health): An article from: Internal Medicine News by Bruce K. Dixon (Author) This digital document is an article from Internal Medicine News, published by Thomson Gale on November 1, 2006. The length of the article is 1698 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Hormone therapy debate continues post WHI: the effects of postmenopausal HT on both heart disease risk and breast cancer risk remain unclear.(Women's Health) Author: Bruce K. Dixon Publication: Internal Medicine News (Magazine/Journal) Date: November 1, 2006 Publisher: Thomson Gale Volume: 39 Issue: 21 Page: 24(1) Distributed by Thomson... | |
 |
Postmenopausal Hormone Therapy: Weighing the Benefits and Risks (NCME Video 695) Also With: Leon Speroff (Primary Contributor), Network For Continuing Medical Education (Primary Contributor) |
|
Close follow-up OK for many small ovarian cysts. (Asymptomatic Postmenopausal Women).: An article from: Family Practice News by Sherry Boschert (Author) This digital document is an article from Family Practice News, published by International Medical News Group on February 1, 2003. The length of the article is 611 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Close follow-up OK for many small ovarian cysts. (Asymptomatic Postmenopausal Women). Author: Sherry Boschert Publication: Family Practice News (Magazine/Journal) Date: February 1, 2003 Publisher: International Medical News Group Volume: 33 Issue: 3 Page: 41(1) Distributed by Thomson... | |
|
Primary Hyperparathyroidism of Post-Menopausal Women: Prospective Population-Based Case-Control Analysis on Prevalence, Clinical Findings and Treatment ... Summaries of Uppsala Dissertations, 820) by Ewa Lundgren (Author) | |
|
Raloxifene linked to reduced risk of stroke, TIA. (In High-Risk, Postmenopausal Women).(transient ischemic attack): An article from: Internal Medicine News by Mitchel L. Zoler (Author) This digital document is an article from Internal Medicine News, published by International Medical News Group on January 15, 2003. The length of the article is 996 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Raloxifene linked to reduced risk of stroke, TIA. (In High-Risk, Postmenopausal Women).(transient ischemic attack) Author: Mitchel L. Zoler Publication: Internal Medicine News (Magazine/Journal) Date: January 15, 2003 Publisher: International Medical News Group Volume: 36 Issue: 2 Page: 45(1) Distributed by Thomson... |
| © 2009 BrightSurf.com |